Statement: in the primary clinical trial, two distinct measurements are reported, covering all three cohorts, in the results section.
Primary_evidence: Outcome Measurement:    Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval.   Time frame: Baseline Results 1:    Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.   Overall Number of Participants Analyzed: 92   Measure Type: Number   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86   Proportion of SNs (PICG) detected by ICG method: 0.95